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varied from 0 to 46.8% (median 4.2%) in the primary tumour. The 
Tmax/Mmean ranged from 1.37 to 4.23 (median 1.98). There was 
no correlation between lesion size and SUVmax or between lesion 
size and HF, which suggests that larger tumours are not 
necessarily more hypoxic than smaller tumours. A significant 
correlation between Tmax/Mmean and HF was observed (rho = 
0.83, p < 0.001), and between SUVmax and HF (rho = 0.74, p = 
0.004). This may suggest that tumours with a higher SUVmax (ie. 
higher intensity of hypoxia) also have a larger proportional 
volume of hypoxia.  
Conclusions: 18F-FAZA PET scans provide a feasible non-invasive 
method to assess NSCLC tumour hypoxia. A hypoxic volume, as 
detected by 18F-FAZA PET, was present in the majority of NSCLC 
patients in our study. Ongoing trial accrual and follow up of our 
patient cohort will provide more information with regards to the 
imaging and clinical value of 18F-FAZA PET, and we hope to 
correlate these imaging metrics with clinical outcomes. 
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Purpose: Radiotherapy (RT) practice variability in the palliative 
setting is well-documented. Clinical practice guidelines inform 
standardized, evidence-based, beneficial practice, while 
simultaneously discouraging unnecessary or potentially harmful 
practices. The process of creating provincial palliative RT clinical 
practice guidelines is associated with multiple challenges. We 
describe the unique approach required in aligning 
multidisciplinary goals as compared to traditional tumour site-
specific guidelines. 
Methods and Materials: Radiation oncologists from the 
provincial Palliative Care Tumour Team, along with guideline 
specialists from the Guideline Resource Unit, formed the primary 
guideline working group tasked with updating the Palliative RT 
guidelines. Tumour site specific representatives (ex. Central 
Nervous System Tumour Team) were incorporated as needed, as 
well as experts in supportive care, on a guideline by guideline 
basis. For each guideline, a systematic literature review was 
conducted to identify relevant evidence. Recommendations 
were initially developed within the primary working group, then 
revised in collaboration with experts from other disciplines. 
Once working group consensus was reached, guideline 
recommendations were circulated to all radiation oncologists 
and Palliative Tumour Team members for input. After several 
rounds of feedback and modifications, provincial consensus was 
reached. 
Results: Initially, one RT guideline had been created for all 
provincial palliative RT recommendations. These guidelines have 
since been split into smaller, more functional palliative RT 
guidelines: 1) Brain Metastases; 2) Bone Metastases and Spinal 
Cord Compression; 3) Bleeding and Gastrointestinal Obstruction; 
and 4) Superior Vena Cava Obstruction, Dyspnea, and 
Hemoptysis. The majority of recommendations were either 
modified or new due to advancements in research or changes in 
consensus based approaches. In total, 70 recommendations were 
approved. Recommendations were supported by a range of 
evidence from high (level one evidence) to low quality 
(consensus opinion). 
Conclusions: By combining the newly updated palliative RT 
guidelines with an educational intervention, variations in 
practice may be mitigated. Using our model, similar efforts can 
be undertaken in other jurisdictions. 
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Purpose: Stereotactic ablative body radiotherapy (SABR) is an 
emerging modality in patients with liver cancer who are 
ineligible for other local therapies. It has been shown to be 
effective with respect to long-term tumour control with minimal 
toxicity. However SABR for liver cancer is not current standard 
of practice despite its potential promise. In order to validate 
increased offering of this promising therapy, objective 
systematic data regarding impact on quality of life (QOL) is 
required. No systematic reviews to date have been performed to 
analyze QOL for primary or metastatic liver cancers. QOL metrics 
are a critical part of therapy evaluation, particularly in disease 
states with short life expectancy. The purpose of this study was 
to conduct a systematic review of evidence surrounding QOL for 
liver SABR.  
Methods and Materials: MEDLINE and EMBASE databases from 
1996 to October 2015 were queried to obtain English language 
studies analysing QOL following SABR for liver cancers. Included 
studies involved patient-reported QOL as either a primary or 
secondary endpoint, along with analysis of QOL change over 
time. Studies were screened by three reviewers, while relevant 
data were abstracted and analyzed by a single reviewer.  
Results: Of 2181 initially screened studies, five met all inclusion 
criteria and were analyzed. Extracted study dates ranged from 
2008 to 2015, included a total of 388 eligible patients, and 4/5 
studies were prospective in design. All were published studies, 
with the exception of one conference abstract. Studies included 
patients with hepatocellular carcinoma, liver metastases and 
intrahepatic cholangiocarcinoma. Extracted studies were 
heterogeneous in dose prescription used (11-70 Gy in 3 – 30 
fractions), as well as in QOL metrics (EORTC QLQ C-15 PAL,/C-
30/LM-21, Euroqol 5D, FACT-Hep, FLIC) and final endpoints 
(range: six weeks to 12 months). Despite this there were few 
clinically or statistically significant declines in QOL scores 
following SABR. Four studies demonstrated increased fatigue 
transiently in the first 1-4 weeks, while two studies showed 
transient worsening of appetite at one month; both metrics 
returned to insignificant difference from baseline by the final 
endpoints. All studies showed no significant decline in QOL at 
their respective endpoints. In studies with overlapping QOL 
tools, estimates of three-month post-SABR global QOL were 
similar. 
Conclusions: Results of this systematic review demonstrate well-
preserved post SABR QOL in patients with otherwise untreatable 
liver cancer, despite heterogeneity amongst the individual 
studies themselves. These findings merit further research to 
increase data collection, to validate QOL tools specific to SABR 
for liver cancers, and to support comparative effectiveness trials 
of SABR with other local modalities in liver cancer including 
surgery, chemoembolization and radiofrequency ablation, with a 
focus on QOL outcomes as an important endpoint. 
 
170 
A SYSTEMATIC REVIEW OF METHODOLOGIES, ENDPOINTS AND 
OUTCOME MEASURES IN PHASE III RANDOMIZED TRIALS OF 
INTERVENTIONS FOR RADIATION THERAPY-INDUCED NAUSEA AND 
VOMITING  
Kristopher Dennis1, Rehana Jamani2, Leila Makhani3, Henry 
Lam4, Carlo De Angelis3, Patrick Ciesielski5, Natalie Coburn3, 
Shun Wong3, Edward Chow3 
1University of Ottawa, Ottawa, ON 
2Queen's University, Kingston, ON 
3University of Toronto, Toronto, ON 
4Sunnybrook Health Sciences Centre, Toronto, ON 
5Jagiellonian University Medical College, Krakow, Poland 
CARO 2016 S63 
_________________________________________________________________________________________________________ 
Purpose: Clinical trials in radiation therapy-induced nausea and 
vomiting (RINV) appear to have varied methodologies, endpoints 
and outcome measures. This variability hinders implementation 
of trial results. A comprehensive analysis of RINV trial design 
elements is lacking. 
Methods and Materials: Ovid versions of the Cochrane Central 
Register of Controlled Trials, the Cochrane Database of 
Systematic Reviews, EMBASE and MEDLINE to first quarter 2011 
were searched for randomized trials of RINV management 
strategies. 
Results: From 599 references in the initial database search we 
selected 34 trials for analysis that collectively randomized 4529 
patients. Twenty-eight trials (82%) were published prior to the 
year 2000. Twenty-seven trials (79%) involved multiple fraction 
radiation therapy (RT) and seven (21%) single fraction RT. 
Twenty-four trials (71%) evaluated prophylactic interventions 
and nine (26%) rescue interventions. Thirty-three trials (97%) 
evaluated pharmacologic interventions. Nausea was not defined 
in any trial but was reported as a stand-alone symptom in 26 
trials (76%) and was graded in 20 (59%), with discrete choice 
categorical qualitative scales being the most common method. 
Vomiting was defined in three trials (9%), reported as a stand-
alone symptom in 17 (47%) and was graded in seven (21%), with 
continuous numerical scales being the most common method. 
Retching was defined in three trials (9%), was not reported as a 
stand-alone symptom in any trial and was graded in one (3%). 
Twenty-one trials (62%) created compound symptom measures 
that combined individual symptoms. Fifteen trials (44%) reported 
on “emetic episodes/events” but only nine of these defined 
them. Seventeen trials (50%) reported on complicated endpoints 
such as “response,” “control” and “success” that factored in 
multiple symptom or compound symptom measures, but seven of 
these did not define them comprehensively. Only 10 trials (29%) 
defined a primary endpoint a priori. 
Conclusions: Methodologies, endpoints and outcome measures 
varied considerably among 34 randomized trials in RINV. 
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Purpose: To systematically review the efficacy and safety of 
various antiemetics in prophylaxis of radiation-induced nausea 
and vomiting (RINV). 
Methods and Materials: A literature search of Ovid MEDLINE, 
EMBASE and Cochrane CENTRAL was performed to identify 
randomized controlled trials (RCTs) that evaluated the efficacy 
of prophylaxis for RINV in patients receiving radiotherapy to 
abdomen/pelvis, including total body irradiation (TBI). Primary 
endpoints were complete control of nausea and complete control 
of vomiting during acute and delayed phases. Secondary 
endpoints included use of rescue medication, quality of life and 
incidence of adverse events. 
Results: Seventeen RCTs were identified. Among patients 
receiving radiotherapy to abdomen/pelvis, our meta-analysis 
showed that 5-hydroxytryptamine-3 receptor antagonists (5HT3 
RAs) were significantly more efficacious than placebo and 
dopamine antagonists in both complete control of vomiting (OR 
0.49, 95% confidence interval [CI] 0.33-0.72 and OR 0.17, 95% CI 
0.05-0.58 respectively) and complete control of nausea (OR 0.43, 
95% CI 0.26-0.70 and OR 0.46, 95% CI 0.24-0.88 respectively). 
5HT3 RAs were also more efficacious than rescue therapy and 
dopamine antagonists plus dexamethasone. The addition of 
dexamethasone to 5HT3 RA compared to 5HT3 RA alone provides 
a modest improvement in prophylaxis of RINV. Among patients 
receiving TBI, 5HT3 RA was more effective than other agents 
(placebo, combination of metoclopramide, dexamethasone and 
lorazepam). 
Conclusions: 5HT3 RAs are more effective than other 
antiemetics for prophylaxis of RINV in patients receiving 
radiotherapy to abdomen/pelvis and TBI. Future RCTs should 
investigate the efficacy of newer agents such as aprepitant in 
addition to 5HT3 RAs in prophylaxis of RINV during both acute 
and delayed phases. 
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Purpose: The British Columbia Cancer Agency radiotherapy (RT) 
program started the Prospective Outcomes and Support Initiative 
(POSI) at all six centres in 2013 to collect and utilize patient 
reported outcomes (PROs) for immediate clinical care, quality 
improvement, and research. We sought to explore the feasibility 
and utility of using PRO two years after the start of POSI. 
Methods and Materials: PROs were collected at time of CT 
simulation via tablet or radiation therapist questions, and 2-4 
weeks post-RT over the phone with a registered nurse (RN). 
Descriptive Statistics were used to present accrual and utility of 
PRO data. Comparison in accrual rates between categories was 
performed with chi square tests. Mean differences in time that 
RNs spent on POSI phone calls were compared with t-tests. 
Multivariable logistic regression modeling identified factors 
associated with successful accrual. 
Results: From May 2013 to July 2015, 2849 patients were 
approached by POSI on 5,847 occasions for patients treated with 
RT for bone metastases (81%), brain metastases (12%), and 
incurable lung cancer (7%). The accrual rate for all encounters 
was 76% (n = 4904), ranging from 73% to 87% depending on cancer 
centre (p < 0.001), and highest amount patients with bone 
metastases (78%), followed by lung cancer (75%) and brain 
metastases (65%; p < 0.001). Patients were significantly less 
likely to be successfully accrued at follow up compared to 
baseline (OR = 0.21; 95% CI = 0.18 – 0.24; p < 0.001), as were 
those with brain metastases (OR = 0.50; 0.41 – 0.1; p < 0.001). 
During the study period RNs made 2042 telephone follow up calls, 
totaling 250 RN hours, to both collect PRO, and subsequently use 
these PRO to guide follow up care. The RN-reported mean time 
to complete the follow up call was highest with brain metastases 
(13.1 minutes) compared to lung cancer (8.2 minutes) and bone 
metastases (6.7 minutes), which was highly significant (p < 
0.001). The RN phone calls that required the RN to offer 
additional support were significantly longer than phone calls 
where no support was needed (mean 12.1 versus 6.4 minutes; p 
< 0.001). From this database we have demonstrated similar 
patient reported pain improvement with single versus multiple 
fraction RT (presented previously), and have used data to lead 
quality improvement initiatives, such as identifying patients who 
did not have a dexamethasone weaning protocol. Other quality 
improvement and research utility of the POSI database will be 
described. 
Conclusions: Population-based collection and utilization of PRO 
for clinical care, quality improvement, and research is feasible 
and associated with only a modest increase in resources and 
workload. Further research is needed on how to best incorporate 
